Precigen, Inc. (PGEN) Stock

Precigen, Inc. (PGEN) is a Healthcare stock trading at $4.80 (as of 2026-06-18), with a market capitalization of $1.55B and a trailing P/E of -3.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Precigen, Inc. develops gene and cellular therapies and offers disease-modifying therapeutics, including related technology platforms such as UltraVector and AdenoVerse and therapy approaches like UltraCAR-T and RheoSwitch. It also develops genetically engineered swine for regenerative medicine and provides reproductive and embryo transfer technologies.

Valuation — source: SEC EDGAR (first-party)
Price	$4.80
Market Cap	$1.55B
P/E Ratio	-3.6
EV / EBITDA	-18.1
Price / Book	76.46
Price / Sales	48.97
DCF Value (model)	$-4.50
DCF Upside vs Price	-193.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$9.68M
Net Margin	-2588.2%
Return on Equity	-1010.2%
Debt / Equity	4.62
Current Ratio	4.82
Revenue Growth (YoY)	1633.9%
EPS Growth (YoY)	-88.9%
FCF Growth (YoY)	160.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	-15.19 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-117.1%
vs Industry	-120.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Patient Capital Management, LLC ($68.95M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Helen Sabzevari
Employees	143
Country	US
IPO Date	2013-08-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.